Pleurisy Market to Reach USD 3.23 Billion by 2032

The global Pleurisy Market is witnessing steady growth as rising respiratory diseases, advancements in diagnostic imaging, and increasing investments in precision healthcare improve the diagnosis and management of pleural disorders. According to Stellar Market Research, the Pleurisy Market was valued at USD 1.83 billion in 2024 and is expected to reach USD 3.23 billion by 2032, growing at a CAGR of 6.94% during the forecast period (2025–2032).

Growing Burden of Respiratory Diseases Fuels Market Expansion

Pleurisy, also known as pleuritis, is an inflammatory condition affecting the pleura surrounding the lungs, often causing severe chest pain during breathing. The condition frequently develops as a complication of respiratory illnesses such as pneumonia, tuberculosis, pulmonary embolism, viral infections, lung cancer, and autoimmune diseases.

The increasing prevalence of these underlying disorders worldwide is significantly driving demand for advanced diagnostic tools, effective medications, minimally invasive procedures, and comprehensive respiratory care. Healthcare providers are placing greater emphasis on early diagnosis to prevent complications such as pleural effusion and chronic respiratory impairment.

As healthcare systems strengthen their respiratory disease management capabilities, the market continues to benefit from higher diagnostic rates and improved patient awareness.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://www.stellarmr.com/report/req_sample/pleurisy-market/2612

Advanced Imaging Technologies Transform Diagnosis

One of the most significant developments in the Pleurisy Market is the widespread adoption of modern diagnostic imaging technologies. Accurate diagnosis remains essential because pleurisy symptoms often resemble those of other respiratory conditions.

Healthcare facilities increasingly rely on:

Computed Tomography (CT) scans
Magnetic Resonance Imaging (MRI)
Chest ultrasound
Digital X-ray imaging
Blood testing
Thoracentesis
Pleural biopsy

These advanced diagnostic techniques enable physicians to accurately identify pleural inflammation, determine underlying causes, and initiate appropriate treatment much earlier than conventional diagnostic methods.

Improved imaging resolution and greater accessibility to diagnostic equipment have significantly enhanced patient outcomes while reducing diagnostic uncertainty.

Artificial Intelligence Creates New Growth Opportunities

Artificial intelligence is beginning to reshape respiratory disease diagnosis across the healthcare industry. AI-assisted imaging analysis enables clinicians to identify subtle abnormalities within pleural tissues more efficiently while reducing diagnostic delays.

Machine learning algorithms can assist radiologists by analyzing CT scans and chest images with greater consistency, helping differentiate pleurisy from pneumonia, tuberculosis, and other pulmonary disorders.

Telemedicine platforms are also expanding access to respiratory specialists, particularly in underserved and rural communities. Remote consultations combined with AI-powered clinical decision support systems allow earlier intervention while reducing unnecessary hospital visits.

These technological innovations are expected to create substantial long-term growth opportunities throughout the forecast period.

Medication-Based Treatment Remains the Preferred Approach

Treatment strategies largely depend on identifying the underlying cause of pleurisy. Medication-based treatment continues to dominate the market due to its effectiveness across multiple disease categories.

Common therapeutic options include:

Non-steroidal anti-inflammatory drugs (NSAIDs)
Antibiotics
Corticosteroids
Antiviral medications
Pain management therapies

In more severe cases involving pleural effusion or persistent inflammation, physicians may perform procedures such as thoracentesis, pleurodesis, or surgical intervention.

Ongoing pharmaceutical research continues to improve treatment outcomes through more targeted anti-inflammatory therapies and advanced respiratory medicines.

Hospitals Continue to Lead Healthcare Demand

Hospitals and specialty clinics remain the largest end users within the Pleurisy Market because complex respiratory cases frequently require advanced imaging equipment, multidisciplinary specialists, and inpatient care.

Diagnostic centers are also experiencing increasing demand due to rising utilization of imaging technologies during early disease evaluation.

Meanwhile, home healthcare services are gradually expanding for patients requiring long-term respiratory monitoring, oxygen therapy, or extended medication management following hospitalization.

Growing healthcare infrastructure investments across developing economies are expected to strengthen access to pleurisy diagnosis and treatment over the coming years.

Regional Outlook

North America currently dominates the global Pleurisy Market due to its advanced healthcare infrastructure, widespread availability of diagnostic imaging technologies, and high prevalence of respiratory diseases. Extensive insurance coverage and continuous investment in medical research further support regional market growth.

Europe represents another major market, benefiting from well-established healthcare systems, strong government support for respiratory disease management, and widespread adoption of innovative diagnostic technologies.

Asia-Pacific is expected to record the fastest growth throughout the forecast period. Countries such as China, India, and Japan are investing heavily in healthcare infrastructure while expanding access to advanced diagnostic facilities. Rising air pollution, increasing tuberculosis cases, and growing public awareness regarding respiratory diseases continue to drive market expansion across the region.

Latin America, the Middle East, and Africa also present promising opportunities as healthcare accessibility improves and governments invest in respiratory disease prevention programs.

Challenges Limiting Market Growth

Despite encouraging growth prospects, several challenges continue to affect the Pleurisy Market.

Limited public awareness remains a significant obstacle, particularly in developing regions where many patients mistake pleurisy symptoms for common respiratory infections. Delayed diagnosis often results in disease progression and increased healthcare costs.

The similarity between pleurisy symptoms and other pulmonary conditions also contributes to misdiagnosis, highlighting the need for more accurate diagnostic technologies and greater physician awareness.

Access to advanced imaging equipment remains uneven across many low-income healthcare systems, potentially limiting early diagnosis and effective treatment.

Competitive Landscape

The Pleurisy Market features numerous pharmaceutical companies, medical device manufacturers, and diagnostic technology providers focused on improving respiratory healthcare.

Leading organizations continue investing in:

AI-assisted diagnostic technologies
Advanced imaging systems
Respiratory disease research
Anti-inflammatory therapies
Vaccine development
Precision medicine
Digital healthcare platforms

Companies including Pfizer, AstraZeneca, GlaxoSmithKline, Roche, Novartis, Sanofi, Merck, Bayer, Cipla, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and several medical device manufacturers continue strengthening their market positions through product innovation and research investments.

Strategic collaborations between pharmaceutical companies, hospitals, diagnostic laboratories, and digital health providers are expected to accelerate future innovation.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://www.stellarmr.com/report/req_sample/pleurisy-market/2612

Future Outlook

The future of the Pleurisy Market remains positive as healthcare systems increasingly prioritize early diagnosis, personalized treatment, and digital healthcare integration. Continued advancements in AI-powered diagnostics, high-resolution imaging technologies, and targeted pharmaceutical therapies are expected to improve patient outcomes while expanding market opportunities.

Growing awareness of respiratory diseases, expanding healthcare infrastructure, and increasing investment in medical innovation will continue supporting steady market growth through 2032. As healthcare providers adopt more sophisticated diagnostic and treatment approaches, the Pleurisy Market is expected to play an increasingly important role in global respiratory care, offering significant opportunities for pharmaceutical companies, medical technology providers, healthcare institutions, and investors.